Immatics N.V.

NASDAQ:IMTX

Biotechnology

Healthcare
$6.10 +1.58%

+$0.15 today

Market cap
$912.78M
Beta
1.30
P/E (TTM)
-5.3
EPS (TTM)
-$1.59
52W Low $5.05High $12.41

Volume 1.57M

Average 0.46M

IMTX Sales of Investments

Cash received from selling or redeeming investments.

Immatics N.V.NASDAQ: IMTX

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments declines year over year

Q1 FY2026 sales of investments of €43.43M fell 85.9% year over year, behind the -50.0% change in trailing-twelve-month sales of investments. Sequentially, it rose 58.4% from the prior quarter. Over 3 fiscal years it compounded at +246.5% a year.

Context

  • Sales of investments amounted to 1094.3% of revenue in FY2025, up 892.5 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -85.9% toward the trailing-twelve-month pace of -50.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
€43.43M+58.4% QoQ
Last fiscal yearDec 2025
€528.16M+68.0% YoY
LTMMar 2026
€282.39M-50.0% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-85.9%——
1 year+68.0%——
3-year CAGR+246.5%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

EUR · from the cash flow

Latest · FY2025
528.16M EUR
Year-over-year change
+68.0%
4-year CAGR
+115.6%

Sales of Investments vs competitors

How IMTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -50.0% is the 7th highest of 10, against a peer median of -36.1%.
  • Sales of investments amounts to 757.1% of revenue for IMTX, versus a peer median of 285.2%.
IMTX Competitors
Sales of Investments for IMTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€10.31B EUR-19.6%+189.9%389.9%
LEGNLegend Biotech CorporationLTM Sep 2026$1.02B USD-79.1%+105.5%75.2%
JANXJanux Therapeutics, Inc.LTM Mar 2026$495.32M USD+176.4%+4.1%2291.8%
IMTXImmatics N.V.LTM Mar 2026€282.39M EUR-50.0%+246.5%757.1%
LYELLyell Immunopharma, Inc.LTM Mar 2026$275.21M USD-52.0%-3.7%887777.4%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$249.82M USD-36.1%-13.3%—
CLLSCellectis S.A.LTM Mar 2026$194.21M USD+230.8%+921.3%285.2%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$125.25M USD-43.8%—1371.0%
IMCRImmunocore Holdings plcLTM Mar 2026$13.99M USD+39.9%—3.6%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$7.89M USD-74.5%-55.9%34.1%
DTILPrecision BioSciences, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding IMTX) —-36.1%+4.1%285.2%

Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(93.34M)37.51M(94.65M)15.22M(188.69M)
Depreciation & Amortization5.26M6.97M7.23M12.23M11.91M
Deferred Income Tax11.15M4.52M06.13M0
Stock-Based Compensation26.4M22.57M20.71M17.64M0
Change in Working Capital(31.7M)37.26M81.63M(163.88M)(42.23M)
Accounts Receivables569K(429K)(2.98M)(1.76M)(232.45K)
Inventory00(84.24M)00
Accounts Payables(31.78M)45.56M84.24M0(36.13M)
Other Working Capital(483K)(7.87M)84.61M(162.11M)(5.87M)
Other Non-Cash Items433K(8.7M)3.31M(45.37M)49.36M
Operating Cash Flow(81.78M)100.13M18.23M(158.03M)(169.66M)
Capital Expenditures(5.66M)(6.22M)(30.96M)(16.48M)(6.3M)
Acquisitions (Net)551K(199.91M)000
Purchases of Investments(11.3M)(216.32M)(415.33M)(450.35M)(324.92M)
Sales of Investments24.45M12.7M414.74M314.44M528.16M
Other Investing Activities(551K)199.96M(8K)(206K)0
Investing Cash Flow7.49M(209.79M)(31.39M)(152.39M)196.7M
Debt Repayment(2.71M)(2.84M)(3.85M)(2.01M)0
Common Stock Issued94K134.48M90.4M343.01M96.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(7.93M)(2.04M)(21.31M)(2.84M)
Financing Cash Flow(2.61M)123.71M84.52M319.68M93.51M
Effect of Forex Changes2.37M1.48M(1.4M)9.01M16.56M
Net Change in Cash(74.54M)15.53M69.95M18.28M137.12M
Free Cash Flow(87.44M)93.92M(12.73M)(174.51M)(175.95M)

Immatics N.V.

NASDAQ:IMTX

Intrinsic Alpha fair value

Locked

Current Price

$6.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.